论文部分内容阅读
目的：探讨G蛋白偶联受体5（LGR5）分子在卵巢癌患者病理组织的表达规律及其意义。方法选择由不同病理类型的卵巢癌肿瘤组织以及正常卵巢组织和卵巢良性腺瘤构建的组织芯片，以大鼠抗人LGR5抗体为第1抗体和辣根过氧化物酶标记的抗大鼠抗体为第2抗体进行免疫组织化学染色，并采用Aperio病理扫描系统结合两位病理科医师进行读片和结果分析。结果正常卵巢组织表达LGR5分子呈阴性（0/2），而卵巢良性腺瘤组织表达LGR5分子呈阴性或弱表达（0/3）。与正常卵巢组织和卵巢良性腺瘤组织相比，LGR5优势表达于卵巢癌组织（68/97，P＜0.05）。结论干细胞标记分子LGR5表达于卵巢癌组织，提示了卵巢癌可能是靶向干预LGR5治疗的潜在靶点。“,”Objective To explore the expression pattern of LGR5 on ovarian cancer.Methods Tissue chips that contain the tumor tissue from 97 ovarian cancer patients and 3 benign ovarian adenoma patients and normal ovarian tissue from 2 patients were stained with rat anti-human LGR5 antibody and HRP labeled anti-rat antibody. And then the tissue chips were analyzed with Aperio pathological scan system and 2 experienced pathologist. ResultsLGR5 was negatively expressed on ovarian adenoma tissues (0/3) and normal ovarian tissues (0/2), and predominantly expressed on some of the ovarian cancer tissues (68/97,P<0.05).Conclusion Stem cell marker LGR5 is expressed on ovarian tumor tissues and it is the promising target of ovarian cancer therapy.